Body Pharm Tesamorelin 32 Pen

The Body Pharm Tesamorelin 32 pen is a GHRH-analogue research format available in South Africa through JCSG.org. With 32mg total peptide content in a dial-and-inject pen, it offers a cost-per-dose advantage for research protocols focused on the GH axis and visceral adipose tissue.

This article covers what the Body Pharm Tesamorelin 32 pen is, how tesamorelin works as a GHRH analogue, what the research evidence shows about its effects on visceral adipose tissue, and how it compares to other GH-axis peptides in the same research category.

Key Takeaways

• The Body Pharm Tesamorelin 32 pen contains 32mg total peptide content in a dial-and-inject mechanism, giving it a strong cost-per-dose advantage over smaller vial formats
• Tesamorelin is a GHRH analogue that preserves pulsatile growth hormone release, with documented efficacy for visceral adipose tissue reduction in HIV-associated lipodystrophy
• The 2025 cardiovascular-outcomes research shows significant risk reduction in people living with HIV treated with tesamorelin, driven by VAT loss and improved lipid parameters
• Tesamorelin is a scheduled medicine under SAHPRA regulation; procure within a legitimate research framework

Specification	Body Pharm Tesamorelin 32 Pen
Total peptide content	32mg (by Body Pharm naming convention) [1][unverified]
Pen mechanism	Dial-and-inject click-wheel [1][unverified]
Format	Pre-filled multi-dose pen
SAHPRA status	Scheduled medicine; research-use supply only

What is the Body Pharm Tesamorelin 32 Pen?

The Body Pharm Tesamorelin 32 pen is a pre-filled, multi-dose GHRH-analogue peptide pen available through JCSG.org South Africa in 2026. The "32" denotes 32mg total peptide content per pen, consistent with Body Pharm's naming convention across its BPC157 & TB500 32 Pen and Retatrutide 32mg pen platforms [1][unverified for tesamorelin].

Attribute	Detail (2026)
Brand	Body Pharm
Format	Pre-filled multi-dose pen
Peptide class	GHRH analogue (tesamorelin)
"32" designation	32mg total content [1][unverified]
Pen mechanism	Dial-and-inject click-wheel [1][unverified]
Positioning	Research use only

Nomenclature caveat

The "32" suffix mirrors Body Pharm's Retatrutide 32mg Pre-Filled Pen naming, where the number denotes total mg content rather than dose count [4]. Until a Body Pharm tesamorelin insert confirms this, treat per-dose calculations as provisional.

Mechanism note

The mechanism is consistent with sibling Body Pharm pens (BPC157/TB500, Retatrutide) that use a dial-a-dose click-wheel. Researchers comparing it against other GHRH analogues such as CJC-1295 should request a leaflet photo before procurement [1][4][unverified].

GHRH Analogue Mechanism — Plain Language

Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs and triggers pulsatile growth hormone (GH) release. That GH then drives hepatic IGF-1 production [1]. Tesamorelin is not exogenous GH; it sits one step upstream in the hypothalamic-pituitary axis.

The axis runs in a short chain:

1. Hypothalamic GHRH is released
2. This stimulates pituitary somatotrophs
3. GH is secreted in pulses
4. The liver and peripheral tissues convert that signal into IGF-1, which mediates most downstream anabolic and lipolytic effects

Tesamorelin slots into the GHRH step. Because the pituitary still controls the release pattern, GH output retains its native pulsatility and remains subject to somatostatin negative feedback [1].

Why the GHRH-vs-GH distinction matters for research design

Direct GH administration produces sustained, non-physiological serum elevations and suppresses endogenous secretion, which alters the feedback loop that normally regulates the axis. A GHRH analogue like tesamorelin preserves the pulsatile release pattern and the feedback loop. This is the mechanistic basis for its observed effect on visceral adipose tissue and lipid profile in the 2025 cardiovascular-outcomes data [1].

For protocol design, tesamorelin models are appropriate when the research question concerns GH-axis modulation rather than supraphysiological GH exposure. Whether pulsatility matters for your specific endpoint is worth checking against the mechanistic literature on GH secretion patterns before choosing between tesamorelin and sustained-release alternatives such as CJC-1295 with DAC.

Quick reference

Property	Tesamorelin
Molecule class	Synthetic GHRH analogue [1]
Amino acid length	44 [1]
Site of action	Pituitary somatotrophs (GHRH receptor) [1]
Downstream signal	Pulsatile GH → hepatic IGF-1 [1]
Registered indication	HIV-associated lipodystrophy (Egrifta) [1]
2025 research interest	Visceral adipose tissue, lipid profile, cardiovascular risk in HIV cohorts [1]

For broader background on the compound, see the tesamorelin peptide overview. For the closest mechanistic relative, compare CJC-1295, which acts on the same GHRH receptor but with a longer half-life profile.

Visceral Adipose Research — What the Studies Show

Tesamorelin is the only GHRH analogue with a registered indication for reducing excess visceral adipose tissue (VAT), specifically in HIV-associated lipodystrophy under the brand name Egrifta [1]. The strongest evidence base sits inside that HIV cohort, where pulsatile GH elevation produces measurable VAT reduction and lipid-profile shifts consistent with lower cardiometabolic risk [1].

The 2025 cardiovascular-outcomes work reports a significant reduction in cardiovascular risk among people living with HIV treated with tesamorelin. This reduction was driven primarily by VAT loss and improved lipid parameters [1]. Emerging research interest also spans lean mass preservation and cognitive function, though these remain exploratory rather than registered indications [1].

What the evidence does and does not support

Endpoint	Evidence status (2026)	Source context
VAT reduction in HIV-lipodystrophy	Registered indication (Egrifta)	FDA-approved formulation [1]
Triglyceride and lipid profile improvement	Supported in HIV cohorts	2025 CV-outcomes data [1]
Cardiovascular risk reduction	Supported in HIV cohorts	2025 study [1]
Non-HIV visceral obesity / NAFLD	Mechanistically plausible, RCT evidence limited	Off-label extrapolation [1]
Muscle mass and cognition	Early-stage research interest	2026 review [1]

Research-use framing

Every efficacy figure above relates to the FDA-approved pharmaceutical formulation studied under clinical-trial conditions. The Body Pharm Tesamorelin 32 pen is sold in South Africa as a research compound for in vitro and non-human laboratory work. No clinical-trial data exist for this specific product, and no claim of human therapeutic equivalence to Egrifta is made or implied here.

Procurement officers should treat the published VAT and lipid data as mechanistic context for protocol design. For broader compound background, see the tesamorelin peptide overview. For the closest GHRH-axis comparator, see CJC-1295.

Body Pharm Tesamorelin 32 Pen — Specifications & Format Advantage

The Body Pharm Tesamorelin 32 pen stands out in the South African research-peptide market for its high-volume reservoir and dial-and-inject precision. Here is how the format compares against standard vialled tesamorelin formats.

Side-by-side specifications

Attribute	Body Pharm Tesamorelin 32 pen	Standard 5mg vial (lyophilised)
Total peptide content	32mg (by Body Pharm naming convention) [1][unverified]	5mg per vial
Reconstitution required	No — pre-filled, ready to use	Yes — bacteriostatic water required
Dose flexibility	User-dialled increments (e.g. 0.25–0.5mg per click) [4][unverified]	Calculated per reconstitution
Septum punctures per lifecycle	One pen, multiple doses	One per vial
Cold-chain band	2–8°C refrigeration throughout	−20°C lyophilised; 2–8°C reconstituted
Other formats	—	Browse all tesamorelin formats

Specifications for the Body Pharm 32 pen are inferred from sibling platform documentation and are [unverified] pending a product insert. Confirm with the supplier before procurement.

Reading the format for procurement

The Body Pharm 32 pen's 32mg reservoir gives it a strong cost-per-dose advantage over smaller vialled formats at any comparable price point. The dial-and-inject mechanism — consistent with Body Pharm's BPC157 & TB500 32 pen platform [4] — allows accurate incremental dosing across multiple research sessions from a single device, reducing waste and simplifying inventory.

For variable-dose research protocols, this means a single pen can serve multiple dosing arms without opening fresh vials. For fixed short-duration work, a smaller vialled format may also suit your protocol; browse all tesamorelin formats.

Pen Format — Why It Matters for Lab Use

Pen format directly affects three line items on a lab's procurement sheet: per-experiment cost, contamination risk during dose preparation, and cold-chain handling between aliquots.

Pre-filled multi-dose pens like the Body Pharm Tesamorelin 32 platform remove the lyophilised-to-solution reconstitution step that vialled tesamorelin requires. This cuts both the bacteriostatic water line item and the number of septum punctures per pen lifecycle. Fewer punctures mean lower bacterial contamination risk and reduced peptide oxidation at the rubber interface — worth noting for any protocol that runs across multiple days from a single reservoir.

For variable-dose research protocols, a dial-and-click pen lets a single device serve multiple dosing arms without opening fresh vials. This matters when an experimental run needs different amounts on different days from the same reservoir, because it reduces waste and simplifies inventory tracking.

Storage is the variable most often mishandled in procurement planning. Lyophilised tesamorelin is typically held at −20°C and reconstituted solutions at 2–8°C. The Body Pharm pen ships pre-solubilised, so the entire device sits in the 2–8°C refrigerated band from receipt through last dose. Confirm the in-use shelf life on the supplied leaflet before costing a multi-week protocol; peptide stability in solution degrades faster than in lyophilised form.

Background on the compound class sits on the tesamorelin peptide overview and the related CJC-1295 GHRH analogue page.

South African Regulatory Context — SAHPRA & Research Chemicals

SAHPRA (the South African Health Products Regulatory Authority) is the competent authority for medicines regulation in South Africa under the Medicines and Related Substances Act 101 of 1965, as amended [1]. Peptides such as tesamorelin supplied under a "research compounds" label are positioned for in vitro and laboratory use only, not for human administration. They are not registered medicines on the SAHPRA register for general use [1].

The "research use only" label does not exempt a product from the Act. SAHPRA's 2023–2025 communications on unregistered injectables and lifestyle peptides make clear that importing, distributing, or selling unregistered scheduled substances for human use without authorisation remains unlawful, regardless of how the listing is worded [1]. Procurement officers should treat the research-chemical framing as a statement of intended use by the supplier, not a regulatory carve-out. The Act applies to the substance itself, not the supplier's marketing claim.

Quick reference — what the labels mean

Term	What it means in SA (2026)	Source
SAHPRA registered medicine	Approved for a specified human indication; carries a registration number	[1]
Schedule 4 / prescription-only	Requires a script from an authorised prescriber for human use	[1]
"Research compound" / "for laboratory use only"	Supplier-applied label; does not override the Act's scheduling	[1]
Unregistered medicine	Not on the SAHPRA register; import/supply for human use restricted	[1]

For mechanism and class background, see the tesamorelin peptide overview and the related CJC-1295 GHRH analogue page.

Disclaimer: This section is general information, not legal or regulatory advice. Classifications change. Confirm the current SAHPRA status of tesamorelin directly with the regulator or a South African regulatory affairs professional before procurement. Products on this page are listed for research use only. Regulatory note last reviewed: June 2026.

Related GHRH & GH-Axis Peptides for Research

Tesamorelin sits within a small group of GH-axis research peptides whose mechanisms differ in clinically meaningful ways. Substitution between them is not straightforward. The table below positions the three compounds most often cross-shopped against the Body Pharm Tesamorelin 32 pen.

Peptide	Class	Mechanistic distinction	Research area	Reference
Tesamorelin	GHRH analogue (native sequence, stabilised)	Mimics endogenous GHRH; drives pulsatile GH and IGF-1; visceral adipose tissue reduction documented in HIV-lipodystrophy cohorts [1]	Visceral fat, lipid profile	This page
CJC-1295 (with DAC)	GHRH analogue with drug affinity complex	DAC modification binds albumin, extending half-life; produces sustained GH elevation rather than preserved pulsatility [1]	Sustained GH/IGF-1 elevation	View
Ipamorelin	Selective GHRP (ghrelin-receptor agonist)	Acts on a different receptor than GHRH analogues; selective for GH release without significant cortisol or prolactin effects [1]	GH secretagogue studies	Browse
MOTS-c	Mitochondrial-derived peptide	Not a GH-axis peptide; acts on AMPK-linked metabolic pathways independent of the somatotrophic axis	Mitochondrial metabolism	Browse

Research areas differ. The CJC-1295 reference page covers the DAC-modified GHRH analogue in more depth for protocols where half-life, not native pulsatility, is the variable under study. Browse all GH-axis peptides on JCSG.org.

Frequently Asked Questions